Login / Signup

Results of a Randomized Phase IIb Trial of Nelipepimut-S + Trastuzumab versus Trastuzumab to Prevent Recurrences in Patients with High-Risk HER2 Low-Expressing Breast Cancer.

G Travis CliftonDiane HaleTimothy J VreelandAnnelies T HickersonJennifer K LittonGheath AlatrashRashmi K MurthyNa QiaoAnne V PhilipsJason J LukasJarrod P HolmesGeorge E PeoplesElizabeth A Mittendorf
Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)
The combination of NPS with trastuzumab is safe. In HER2 low-expressing breast cancer, no significant difference in DFS was seen in the intention-to-treat analysis; however, significant clinical benefit was seen in patients with TNBC. These findings warrant further investigation in a phase III randomized trial.
Keyphrases
  • phase iii
  • epidermal growth factor receptor
  • open label
  • clinical trial
  • metastatic breast cancer
  • phase ii
  • double blind
  • placebo controlled
  • tyrosine kinase
  • study protocol
  • wild type